S&P 500   3,957.04 (+0.59%)
DOW   33,701.88 (+0.31%)
QQQ   283.40 (+1.02%)
AAPL   142.37 (+1.01%)
MSFT   246.96 (+1.06%)
META   115.70 (+1.55%)
GOOGL   94.18 (-0.80%)
AMZN   90.17 (+1.93%)
TSLA   173.31 (-0.42%)
NVDA   170.08 (+5.51%)
NIO   13.35 (+6.12%)
BABA   94.02 (+6.44%)
AMD   69.92 (-0.31%)
T   19.14 (-0.83%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.48 (+0.36%)
AMC   6.18 (+2.15%)
PYPL   74.50 (+0.11%)
PFE   51.52 (+2.55%)
NFLX   309.17 (+0.24%)
S&P 500   3,957.04 (+0.59%)
DOW   33,701.88 (+0.31%)
QQQ   283.40 (+1.02%)
AAPL   142.37 (+1.01%)
MSFT   246.96 (+1.06%)
META   115.70 (+1.55%)
GOOGL   94.18 (-0.80%)
AMZN   90.17 (+1.93%)
TSLA   173.31 (-0.42%)
NVDA   170.08 (+5.51%)
NIO   13.35 (+6.12%)
BABA   94.02 (+6.44%)
AMD   69.92 (-0.31%)
T   19.14 (-0.83%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.48 (+0.36%)
AMC   6.18 (+2.15%)
PYPL   74.50 (+0.11%)
PFE   51.52 (+2.55%)
NFLX   309.17 (+0.24%)
S&P 500   3,957.04 (+0.59%)
DOW   33,701.88 (+0.31%)
QQQ   283.40 (+1.02%)
AAPL   142.37 (+1.01%)
MSFT   246.96 (+1.06%)
META   115.70 (+1.55%)
GOOGL   94.18 (-0.80%)
AMZN   90.17 (+1.93%)
TSLA   173.31 (-0.42%)
NVDA   170.08 (+5.51%)
NIO   13.35 (+6.12%)
BABA   94.02 (+6.44%)
AMD   69.92 (-0.31%)
T   19.14 (-0.83%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.48 (+0.36%)
AMC   6.18 (+2.15%)
PYPL   74.50 (+0.11%)
PFE   51.52 (+2.55%)
NFLX   309.17 (+0.24%)
S&P 500   3,957.04 (+0.59%)
DOW   33,701.88 (+0.31%)
QQQ   283.40 (+1.02%)
AAPL   142.37 (+1.01%)
MSFT   246.96 (+1.06%)
META   115.70 (+1.55%)
GOOGL   94.18 (-0.80%)
AMZN   90.17 (+1.93%)
TSLA   173.31 (-0.42%)
NVDA   170.08 (+5.51%)
NIO   13.35 (+6.12%)
BABA   94.02 (+6.44%)
AMD   69.92 (-0.31%)
T   19.14 (-0.83%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.48 (+0.36%)
AMC   6.18 (+2.15%)
PYPL   74.50 (+0.11%)
PFE   51.52 (+2.55%)
NFLX   309.17 (+0.24%)
NASDAQ:ONCS

OncoSec Medical - ONCS Stock Forecast, Price & News

$2.17
-0.18 (-7.66%)
(As of 12/8/2022 02:08 PM ET)
Add
Compare
Today's Range
$2.14
$2.30
50-Day Range
$2.35
$101.20
52-Week Range
$2.28
$34.76
Volume
1,110 shs
Average Volume
2.51 million shs
Market Capitalization
$3.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.00

OncoSec Medical MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4,969.1% Upside
$110.00 Price Target
Short Interest
Healthy
1.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of OncoSec Medical in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$105 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

ONCS stock logo

About OncoSec Medical (NASDAQ:ONCS) Stock

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Stock News Headlines

OncoSec Announces Pricing of $3.5 Million Public Offering
OncoSec provides updates on cancer programs in new filing
OncoSec Announces Reverse Stock Split
OncoSec Cuts Workforce, Prioritizes Pipeline
OncoSec Medical to Restructure, Cut Jobs
OncoSec Medical To Reduce Staff By About 45%
Robert Arch joins OncoSec Medical as CEO
OncoSec appoints new finance chief
OncoSec Hikes on Start of Clinical Trial
See More Headlines
Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Company Calendar

Last Earnings
12/14/2021
Today
12/08/2022
Next Earnings (Estimated)
12/21/2022
Fiscal Year End
7/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCS
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$110.00
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$110.00
Forecasted Upside/Downside
+4,969.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-34,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.42 per share

Miscellaneous

Free Float
1,755,000
Market Cap
$3.91 million
Optionable
Not Optionable
Beta
1.48

Key Executives

  • Dr. Robert H. Arch Ph.D. (Age 56)
    Pres, CEO & Non-Independent Director
    Comp: $159.16k
  • Mr. George Chi C.F.A. (Age 53)
    CPA, CFO, Exec. VP of Fin., Sec. &Treasurer
    Comp: $371.01k
  • Mr. Robert J. DelAversano CPAMr. Robert J. DelAversano CPA (Age 50)
    VP of Fin. and Principal Accounting Officer & Controller
    Comp: $410.15k
  • Dr. Kim Jaffe
    Assistant VP of Bus. Devel. & Operations
  • Mr. Tu Diep M.Sc.
    Sr. VP & Head of Operations
  • Dr. Sandra Aung Ph.D.
    Sr. VP & Chief Clinical Devel. Officer
  • Dr. Mai Hope Le M.D. (Age 46)
    Consultant













ONCS Stock - Frequently Asked Questions

Should I buy or sell OncoSec Medical stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ONCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCS, but not buy additional shares or sell existing shares.
View ONCS analyst ratings
or view top-rated stocks.

What is OncoSec Medical's stock price forecast for 2023?

1 Wall Street analysts have issued twelve-month price targets for OncoSec Medical's stock. Their ONCS share price forecasts range from $110.00 to $110.00. On average, they expect the company's share price to reach $110.00 in the next twelve months. This suggests a possible upside of 4,832.7% from the stock's current price.
View analysts price targets for ONCS
or view top-rated stocks among Wall Street analysts.

How have ONCS shares performed in 2022?

OncoSec Medical's stock was trading at $21.1112 at the beginning of the year. Since then, ONCS shares have decreased by 89.4% and is now trading at $2.23.
View the best growth stocks for 2022 here
.

Are investors shorting OncoSec Medical?

OncoSec Medical saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 16,700 shares, an increase of 496.4% from the October 31st total of 2,800 shares. Based on an average daily trading volume, of 298,300 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.9% of the shares of the stock are sold short.
View OncoSec Medical's Short Interest
.

When is OncoSec Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 21st 2022.
View our ONCS earnings forecast
.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) announced its quarterly earnings data on Tuesday, December, 14th. The biotechnology company reported ($5.50) earnings per share for the quarter, topping analysts' consensus estimates of ($8.14) by $2.64.

When did OncoSec Medical's stock split?

OncoSec Medical's stock reverse split before market open on Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (40.02%) and Renaissance Technologies LLC (3.76%). Insiders that own company stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano, Robert J Delaversano, Sara Bonstein and Yuhang Zhao.
View institutional ownership trends
.

How do I buy shares of OncoSec Medical?

Shares of ONCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $2.23.

How much money does OncoSec Medical make?

OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $4.01 million. The biotechnology company earns $-34,180,000.00 in net income (profit) each year or ($20.8791) on an earnings per share basis.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for the company is www.oncosec.com. The biotechnology company can be reached via phone at (858) 662-6732, via email at investors@oncosec.com, or via fax at 858-430-3832.

This page (NASDAQ:ONCS) was last updated on 12/8/2022 by MarketBeat.com Staff